Nature Genetics, Год журнала: 2019, Номер 51(10), С. 1450 - 1458
Опубликована: Сен. 30, 2019
Язык: Английский
Nature Reviews Disease Primers, Год журнала: 2019, Номер 5(1)
Опубликована: Сен. 23, 2019
Язык: Английский
Процитировано
2284
Genes & Development, Год журнала: 2018, Номер 32(19-20), С. 1267 - 1284
Опубликована: Окт. 1, 2018
The presence of inflammatory immune cells in human tumors raises a fundamental question oncology: How do cancer avoid the destruction by attack? In principle, tumor development can be controlled cytotoxic innate and adaptive cells; however, as develops from neoplastic tissue to clinically detectable tumors, evolve different mechanisms that mimic peripheral tolerance order tumoricidal attack. Here, we provide an update recent accomplishments, unifying concepts, future challenges study tumor-associated cells, with emphasis on metastatic carcinomas.
Язык: Английский
Процитировано
1767
Genes & Diseases, Год журнала: 2018, Номер 5(2), С. 77 - 106
Опубликована: Май 12, 2018
As the most commonly occurring cancer in women worldwide, breast poses a formidable public health challenge on global scale. Breast consists of group biologically and molecularly heterogeneous diseases originated from breast. While risk factors associated with this varies respect to other cancers, genetic predisposition, notably mutations
Язык: Английский
Процитировано
1184
Cancer Discovery, Год журнала: 2019, Номер 9(2), С. 176 - 198
Опубликована: Янв. 24, 2019
Abstract Triple-negative breast cancer (TNBC) remains the most challenging subtype to treat. To date, therapies directed specific molecular targets have rarely achieved clinically meaningful improvements in outcomes of patients with TNBC, and chemotherapy standard care. Here, we seek review recent efforts classify TNBC based on comprehensive profiling tumors for cellular composition features. Technologic advances allow tumor characterization at ever-increasing depth, generating data that, if integrated clinical–pathologic features, may help improve risk stratification patients, guide treatment decisions surveillance, identify new drug development. Significance: is characterized by higher rates relapse, greater metastatic potential, shorter overall survival compared other major subtypes. The identification biomarkers that can a unmet need. Understanding mechanisms drive resistance key design novel therapeutic strategies prevent development disease and, ultimately, this patient population.
Язык: Английский
Процитировано
1077
Nature, Год журнала: 2019, Номер 575(7781), С. 210 - 216
Опубликована: Окт. 23, 2019
Abstract Metastatic cancer is a major cause of death and associated with poor treatment efficacy. A better understanding the characteristics late-stage required to help adapt personalized treatments, reduce overtreatment improve outcomes. Here we describe largest, our knowledge, pan-cancer study metastatic solid tumour genomes, including whole-genome sequencing data for 2,520 pairs normal tissue, analysed at median depths 106× 38×, respectively, surveying more than 70 million somatic variants. The characteristic mutations lesions varied widely, that reflect those primary types, high rates duplication events (56%). Individual were relatively homogeneous, vast majority (96%) driver being clonal up 80% tumour-suppressor genes inactivated bi-allelically by different mutational mechanisms. Although genomes showed similar landscape tumours, find could contribute responsiveness therapy or resistance in individual patients. We implement an approach review clinically relevant associations their potential actionability. For 62% patients, identify genetic variants may be used stratify patients towards therapies either have been approved are clinical trials. This demonstrates importance comprehensive genomic profiling precision medicine cancer.
Язык: Английский
Процитировано
922
Nature, Год журнала: 2020, Номер 578(7793), С. 122 - 128
Опубликована: Фев. 5, 2020
Cancer develops through a process of somatic evolution
Язык: Английский
Процитировано
914
Cancer Cell, Год журнала: 2018, Номер 34(3), С. 427 - 438.e6
Опубликована: Сен. 1, 2018
Язык: Английский
Процитировано
818
Cell, Год журнала: 2018, Номер 173(3), С. 581 - 594.e12
Опубликована: Апрель 1, 2018
Clear-cell renal cell carcinoma (ccRCC) exhibits a broad range of metastatic phenotypes that have not been systematically studied to date. Here, we analyzed 575 primary and 335 biopsies across 100 patients with ccRCC, including two cases sampledat post-mortem. Metastatic competence was afforded by chromosome complexity, identify 9p loss as highly selected event driving metastasis ccRCC-related mortality (p = 0.0014). Distinct patterns dissemination were observed, rapid progression multiple tissue sites seeded tumors monoclonal structure. By contrast, observed attenuated in characterized high tumor heterogeneity, acquired gradually initial solitary metastasis. Finally, early divergence primitive ancestral clones protracted latency up decades feature pancreatic metastases.
Язык: Английский
Процитировано
726
Cell, Год журнала: 2020, Номер 184(2), С. 404 - 421.e16
Опубликована: Дек. 23, 2020
Язык: Английский
Процитировано
631
Nature, Год журнала: 2019, Номер 569(7757), С. 560 - 564
Опубликована: Май 1, 2019
Язык: Английский
Процитировано
600